{
    "2021-09-14": [
        [
            {
                "time": "2021-06-30",
                "original_text": "复星医药：作为国内首个上市的个性化细胞治疗产品，奕凯达为二线以后的淋巴瘤患者带来了持续缓解的可能性",
                "features": {
                    "keywords": [
                        "复星医药",
                        "个性化细胞治疗",
                        "奕凯达",
                        "淋巴瘤",
                        "持续缓解"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-30",
                "original_text": "复星医药：截至2021年6月30日，集团已有共计19个已通过或视为通过仿制药一致性评价的产品在五批药品集采招标中中标",
                "features": {
                    "keywords": [
                        "复星医药",
                        "仿制药",
                        "一致性评价",
                        "药品集采",
                        "中标"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-09-14",
                "original_text": "复星医药(02196)：复宏汉霖拟为其控股子公司汉霖制药不超3亿元债务提供担保 大额借贷担保",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复宏汉霖",
                        "汉霖制药",
                        "债务担保",
                        "大额借贷"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-09-14",
                "original_text": "复星医药：本集团实际对外担保金额按2021年9月14日汇率折合人民币约203.75亿元 大额借贷担保",
                "features": {
                    "keywords": [
                        "复星医药",
                        "对外担保",
                        "大额借贷",
                        "汇率"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}